Table 1 Baseline screening, assessment, and follow-up schedule

Follow-up time window (days)

±2

±2

±2

±7

±7

±7

±7

±7

Informed consent

●

Demographic characteristics

●

Socioeconomic status

●

Medical history

●

Information on tumor clinical evaluation and surgical operation

●

Physical examination

●

Blood routine examination

●

●

●

●

●

●

Blood clotting function

●

Routine urine test

●

●

●

●

●

●

Routine stool test

●

●

●

●

●

●

Blood biochemistry

●

●

●

●

●

●

Hormone testing^a

●

●

●

●

●

●

●

Tumor biomarkers^b

●

●

●

●

●

●

●

Gynecological examination^c

●

●

●

●

●

●

●

Abdominal/pelvic CT/MRI

●

Chess X-ray

●

●

●

●

●

●

Randomization

●

Assessment of residual urine^d

●

●

●

●

●

●

Uroflowmetry

●

●

Urodynamic tests

●

Anorectal function evaluation

●

Pelvic floor functional testing

●

●

EQ-5D^e

●

●

●

●

PISQ-12^f

●

●

●

PFDI-20^g

●

●

●

●

ICIQ/OABss^h

●

●

●

●

Adverse events

●

●

●

●

●

●

●